Asterisks indicate a significant difference in comparison with the unstimulated control at P < 0.01. To further support the inflammatory property of the recombinant SspA, we compared the SspA-deficient mutant G6G and the parental strain for their capacity to induce of IL-1β, TNF-α, IL-6, CXCL8 and CCL5 secretion in macrophages. The MTT test revealed that macrophage viability was not significantly reduced (less than 10%) by a treatment with cells of S. suis P1/7 or G6G at MOI of 100. As reported in Table 2, the TH-302 clinical trial amounts of IL-1β, TNF-α and IL-6 secreted by macrophages were significantly

lower for the SspA-deficient mutant compared to the parental strain. More specifically, IL-1β, TNF-α and IL-6 production were decreased by 26%, 43% and 41%, respectively. In contrast, the amounts of CCL5 and to a lesser

extent CXCL8 were significantly higher when macrophages were stimulated with SspA-deficient mutant (G6G) compared to https://www.selleckchem.com/products/shp099-dihydrochloride.html PD0325901 ic50 the parental strain. Table 2 Cytokine secretion by PMA-differentiated U937 macrophages following stimulation with S. suis P1/7 and its SspA deficient mutant G6G. Strain Amount secreted of cytokines (pg/ml)   IL-1β TNF-α IL-6 CXCL8 CCL5 Control 51 ± 3 217 ± 2 10 ± 1 5245 ± 432 2116 ± 4 S. suis P1/7 161 ± 8 1800 ± 11 1160 ± 21 611000 ± 756 13355 ± 564 S. suis G6G 120 ± 3* 1030 ± 14* 690 ± 6* 653000 ± 634* 15664 ± 34* The data are the means ± SD of triplicate assays for three separate experiments. Asterisks indicate a significant difference in cytokine secretion by macrophages stimulated with the SspA deficient mutant (G6G) in comparison with the parental strain at P < 0.01. Lastly we investigated the capacity of the SspA protease to degrade CCL5, IL-6 and CXCL8, the tree cytokines produced in higher amounts by macrophages stimulated with the recombinant SspA. Recombinant cytokines were incubated with the SspA protease

at concentrations ranging from 0.26 to 16.5 μg/ml and after 4 h, residual cytokines were determined by ELISA (Figure 2). There was a significant decrease in amounts of CCL5 in presence of SspA, even at low concentrations (0.26 μg/ml). Moreover, a decrease of approximately 20% was also noticed for IL-6 treated with SspA at 16.5 μg/ml. In contrast, there was no decrease for CXCL8 following incubation with Phosphatidylinositol diacylglycerol-lyase SspA. Figure 2 CCL5, IL-6 and CXCL8 degradation by the recombinant SspA of S. suis. A value of 100% was assigned to the amounts of cytokines detected in the absence of SspA. The data are means ± SD of triplicate assays from three separate experiments. Asterisks indicate a significant difference in comparison with the control (no SspA) at P < 0.01. Thereafter, in order to identify the mechanism by which the recombinant SspA may activate macrophages, the effect of selected kinase inhibitors on the secretion of IL-6, CXCL8 and CCL5 by macrophages was investigated.